Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.
Isolated cataplexy of more than 40 years’ duration. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study.
Primary progressive narcolepsy type 1: the other side of the coin. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Morbidity and mortality of middle-aged and elderly narcoleptics. Health, social and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Juji, T., Matsuki, L., Tokunaga, K., Naohara, K. International Classification of Sleep Disorders (ICSD-3) 3rd edn (AASM, 2014). Lancet 355, 39–40 (2000).Īmerican Academy of Sleep Medicine. Hypocretin (orexin) deficiency in human narcolepsy. Nishino, N., Ripley, B., Overeem, S., Lammers, G. HLA antigens in Japanese patients with narcolepsy. Discrimination of narcolepsy by using genetic markers and HLA. Studies in psychophysiology of dreams III. Idiopathic narcolepsy: a disease sui generis with remarks on the mechanism of sleep. Criteria for the diagnosis of the narcoleptic syndrome. Eigentümliche mit Einschlafen verbundene Anfälle. More research is needed to understand the clinical spectrum of narcolepsy, the exact mechanisms leading to orexin neuronal loss and the value of new treatments, including orexin agonists and immunomodulation.Īwareness of narcolepsy, assessments of treatment efficacy, treatment of children or during pregnancy and management of comorbidities are still suboptimal in narcolepsy and require improvement.īassetti, C. Several drugs (including modafinil, sodium oxybate, pitolisant, solriamfetol and methylphenidate) improve narcoleptic symptoms in most patients. Patients with narcolepsy type 1 have cataplexy and little or no orexin in cerebrospinal fluid narcolepsy type 2 is a diagnosis of exclusion requiring ancillary tests ruling out other causes of EDS. Narcolepsy arises from the interaction of genetic and environmental factors, which lead to an immune-mediated selective loss or dysfunction of orexin neurons in the lateral hypothalamus. Narcolepsy is a rare and often disabling hypothalamic disorder that presents with sleep–wake dysregulation (excessive daytime sleepiness (EDS), cataplexy, hallucinations, sleep paralysis and disturbed sleep) and motor, cognitive, psychiatric, metabolic and autonomic disturbances. Finally, advances and obstacles in the symptomatic and causal treatment of narcolepsy are reviewed. The limitations of current diagnostic criteria for narcolepsy are discussed, and a possible new classification system incorporating the borderland conditions is presented. Data supporting the view of NT1 as a hypothalamic disorder affecting not only sleep–wake but also motor, psychiatric, emotional, cognitive, metabolic and autonomic functions are presented, along with uncertainties concerning the ‘narcoleptic borderland’, including narcolepsy type 2 (NT2). This Review focuses on our current understanding of how genetic, environmental and immune-related factors contribute to a prominent (but not isolated) orexin signalling deficiency in patients with NT1. Symptomatic treatment with stimulant and anticataplectic drugs is usually efficacious. Diagnosis is based on these clinical features and supported by biomarkers: evidence of rapid eye movement sleep periods soon after sleep onset cerebrospinal fluid orexin deficiency and positivity for HLA-DQB1*06:02.
Narcolepsy type 1 (NT1) is characterized by excessive daytime sleepiness and cataplexy, accompanied by sleep–wake symptoms, such as hallucinations, sleep paralysis and disturbed sleep. Narcolepsy is a rare brain disorder that reflects a selective loss or dysfunction of orexin (also known as hypocretin) neurons of the lateral hypothalamus.
0 kommentar(er)
